Pyoderma Gangrenosum: Recognition and Wound Care Approach

Pyoderma Gangrenosum: What Wound Care Clinicians Must Know

Pyoderma gangrenosum is the wound care diagnosis that punishes clinicians who do not recognize it. A rapidly expanding, painful ulcer with undermined violaceous borders that worsens with debridement — pyoderma gangrenosum (PG) is the condition where standard wound care interventions cause harm. The clinician who derides it as "infected" and performs aggressive debridement triggers pathergy, accelerating tissue destruction. The clinician who recognizes it stops, refers, and saves the patient months of unnecessary suffering.

PG is a neutrophilic dermatosis — an inflammatory, not infectious, condition. It is associated with inflammatory bowel disease, rheumatoid arthritis, hematologic malignancies, and other systemic inflammatory conditions in approximately 50% of cases. The remaining cases are idiopathic. Regardless of the underlying association, the wound care clinician's recognition of PG is the critical event that diverts the patient from escalating surgical intervention toward appropriate immunosuppressive therapy.

The Pathergy Phenomenon

Pathergy is the defining feature that separates PG from nearly every other wound diagnosis. Pathergy is the development of new lesions or worsening of existing lesions in response to minor skin trauma — including surgical debridement, biopsy, and even IV insertion.

What pathergy means for wound care clinicians:

Debridement of a PG ulcer will make it larger, not smaller
Sharp debridement, surgical debridement, and even aggressive wound cleansing can trigger pathergy
Skin grafting over PG ulcers fails and worsens the wound in most cases
Even diagnostic skin biopsy can trigger new lesions at the biopsy site

The clinical trap: A wound care clinician sees a painful, rapidly expanding ulcer with what appears to be necrotic tissue. Standard wound care training says debride. In PG, debridement is the accelerant. The wound worsens. The clinician derides more aggressively. The wound expands further. This cycle can continue through multiple procedures before PG is considered.

This is why recognition is the intervention. Stopping harmful treatment is more important than starting the right treatment.

Clinical Recognition and Differential Diagnosis

Classic PG Presentation

Rapidly progressive, painful ulcer with irregular, undermined, violaceous (purple) borders
The border overhangs the wound bed — probe gently and the edge extends beyond the visible margin
Wound bed may contain necrotic tissue, purulent exudate, and granulation tissue simultaneously
Surrounding skin shows violaceous discoloration that extends beyond the wound edge
Pain is severe and often described as "out of proportion" to the wound size
Common locations: lower extremities (most common), trunk, peristomal sites (post-surgical)
May begin at surgical sites, IV insertion sites, or areas of minor trauma (pathergy)

What PG Is NOT

Differentiating from infection:

PG wound cultures typically grow normal skin flora or are sterile — NOT the polymicrobial pattern expected in true infection
Antibiotics do not improve PG (they may coincidentally seem to help if anti-inflammatory properties overlap)
Systemic infection signs (fever, elevated WBC) may be present due to the inflammatory nature of PG, not infection

Differentiating from vascular ulcers:

Vascular ulcers have distinct etiology markers: venous (hemosiderin staining, lipodermatosclerosis), arterial (pale base, absent pulses, ABI <0.9)
PG has violaceous, undermined borders — vascular ulcers do not

Differentiating from factitial wounds:

PG can be confused with self-inflicted wounds because of the atypical appearance and rapid progression
PG has characteristic histologic findings and associated systemic conditions
Factitial wounds occur in accessible areas, have geometric borders, and lack the violaceous undermined edge

For comprehensive infection assessment protocols that help differentiate true wound infection from inflammatory conditions like PG, structured assessment tools are essential.

Wound Care Management of PG

Once PG is suspected, wound care becomes gentle and supportive. The treatment that heals PG is immunosuppressive therapy prescribed by dermatology or rheumatology — not wound care interventions.

What to Do

Gentle cleansing with normal saline only — no scrubbing, no aggressive irrigation
Moist wound healing: non-adherent primary dressings (silicone-faced foams, petrolatum gauze)
Topical corticosteroids (clobetasol, betamethasone) to the wound edge and periwound skin — this is often the first-line topical treatment prescribed by dermatology
Topical tacrolimus (0.1% or 0.3%) as an alternative or adjunct to topical steroids
Absorptive secondary dressings for exudate management
Pain management: topical lidocaine prior to dressing changes, systemic analgesia coordinated with the treatment team

What NOT to Do

No debridement — not sharp, not surgical, not mechanical, not autolytic with aggressive enzymatic agents
No skin grafting — grafts trigger pathergy and fail
No compression on PG ulcers unless coexisting venous disease is confirmed and PG is controlled
No aggressive wound cleansing — gentle irrigation only
No empiric antibiotics based on wound appearance alone — culture-directed therapy only if true secondary infection is confirmed

Systemic Treatment Coordination

The wound care clinician does not prescribe immunosuppressive therapy but must understand the treatment landscape to coordinate care:

First-line: Systemic corticosteroids (prednisone 0.5–1 mg/kg/day)
Steroid-sparing agents: Cyclosporine, mycophenolate mofetil, dapsone, infliximab, adalimumab
Biologics: TNF-alpha inhibitors (infliximab, adalimumab) for refractory cases
Treatment of the underlying condition (IBD, RA, hematologic malignancy) often improves PG

Documentation for PG

Thorough wound care documentation is particularly important for PG because the diagnosis is clinical, the treatment contradicts standard wound care protocols, and the condition may be subject to clinical dispute.

Document at every visit:

Wound measurements with photo documentation (essential for tracking response to immunosuppressive therapy)
Border characteristics: violaceous color, undermining depth, cribriform scarring pattern
Pain assessment and management
Rationale for NOT debriding — document the clinical reasoning explicitly
Communication with dermatology/rheumatology: date, provider, information exchanged
Response to immunosuppressive therapy: is the border stabilizing, is new tissue emerging, is the wound contracting
Any pathergy events: new lesions at trauma sites, worsening after minor procedures

Key Takeaways

Pathergy is the defining feature of PG: debridement, surgery, and even minor trauma worsen the wound — recognition that stops harmful treatment is the most important clinical intervention
The classic PG presentation is a rapidly expanding, painful ulcer with undermined violaceous borders — this combination should immediately halt standard wound care protocols and trigger dermatology referral
PG is inflammatory, not infectious: wound cultures are typically negative or grow colonizers, and antibiotics do not treat the underlying condition
Wound care for PG is gentle and supportive: saline cleansing, non-adherent dressings, topical steroids to the wound edge, and no debridement of any type
Document the clinical reasoning for NOT debriding explicitly in every note, and record all dermatology/rheumatology coordination to support the non-standard treatment approach